FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Up 100.7% in May

FibroBiologics Inc. (NASDAQ:FBLG) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totaling 237,640 shares, a growth of 100.7% from the April 30th total of 118,414 shares. Based on an average daily trading volume, of 563,635 shares, the days-to-cover ratio is currently 0.4 days. Currently, 5.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FBLG. AQR Capital Management LLC acquired a new position in shares of FibroBiologics during the 1st quarter worth about $29,000. XTX Topco Ltd boosted its position in shares of FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of FibroBiologics during the 2nd quarter worth about $49,000. Cerity Partners LLC boosted its position in shares of FibroBiologics by 37.2% during the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock worth $80,000 after acquiring an additional 34,702 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of FibroBiologics during the 2nd quarter worth about $60,000.

Wall Street Analyst Weigh In

Several research firms recently commented on FBLG. D. Boral Capital reissued a “hold” rating on shares of FibroBiologics in a research note on Thursday, March 26th. Weiss Ratings cut FibroBiologics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday. Wall Street Zen raised FibroBiologics to a “sell” rating in a research note on Saturday, April 4th. Maxim Group cut FibroBiologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price (up from $4.00) on shares of FibroBiologics in a research note on Thursday, April 16th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $74.00.

FibroBiologics Trading Down 6.3%

FBLG traded down $0.07 on Tuesday, hitting $1.05. 99,705 shares of the company were exchanged, compared to its average volume of 274,175. FibroBiologics has a twelve month low of $0.95 and a twelve month high of $19.80. The company has a market cap of $5.47 million, a price-to-earnings ratio of -0.15 and a beta of 1.13. The firm has a 50-day moving average price of $1.72 and a two-hundred day moving average price of $4.49.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.33) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.33). Equities analysts expect that FibroBiologics will post -4.41 EPS for the current year.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.